Press "Enter" to skip to content

PTCT ALERT: Johnson Fistel Encourages Investors to Inquire About PTC Therapeutics Securities Class Action Investigation

Loading…
Loading…

SAN DIEGO, Jan. 25, 2024 (GLOBE NEWSWIRE) — Shareholder rights law firm Johnson Fistel, LLP is investigating whether PTC Therapeutics, Inc. (“PTC” or the “Company”) PTCT, any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose material, adverse information to investors. The investigation focuses on investors’ losses and whether they may be recovered under federal securities laws.

What if I purchased PTC securities? If you purchased securities and suffered significant losses on your investment, join our investigation now:

                        Click Here to Join This Action

Or for more information, contact Jim Baker at jimb@johnsonfistel.com or (619) 814-4471

There is no cost or obligation to you.

What is Johnson Fistel investigating? On September 15, 2023, PTC issued a press release “announc[ing] . . . that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a negative opinion on the conversion of the conditional marketing authorization to full marketing authorization of Translarna™ (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD).  The negative opinion also applies to the renewal of the existing conditional authorization.” 

Then on January 25, 2024, CHMP for a second time issued a negative opinion on Translarna. The negative opinion issued by the Committee will result in the withdrawal of the therapy in Europe.

What if I have relevant nonpublic information? Individuals with nonpublic information regarding the company should consider whether to assist our investigation or take advantage of the SEC Whistleblower program. Under the SEC program, whistleblowers who provide original information may, under certain circumstances, receive rewards totaling up to thirty percent of any successful recovery made by the SEC. For more information, contact Jim Baker at (619) 814-4471 or jimb@johnsonfistel.com.

Loading…
Loading…

About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com.

Attorney advertising.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.

Johnson Fistel, LLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.

Contact:
Johnson Fistel, LLP
501 W. Broadway, Suite 800, San Diego, CA 92101
James Baker, Investor Relations or Frank J. Johnson, Esq., (619) 814-4471
jimb@johnsonfistel.com or fjohnson@johnsonfistel.com


Loading…
Loading…

This post was originally published on this site

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *